We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information to support your recovery after COVID-19.
List of Field Safety Notices from 22 to 26 April 2024.
How a marketing authorisation holder should report a defect with a veterinary medicine.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
Animal bites and pasteurella infections information for healthcare staff.
Batch recall alert for human eye gels that may be prescribed by vets and used under the cascade.
Check the tariff classification for surface-active preparation for washing the skin and the hair (gel 2-in-1).
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Guidance and support on coronavirus (COVID-19) in Scotland.
The characteristics, diagnosis, management, surveillance and epidemiology of Pseudomonas aeruginosa.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
Read about talking therapies and counselling for mental health problems.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
The epidemiology, symptoms, diagnosis and management of plague.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
Clinicians are provided with actions to complete when managing infectious diseases in the asylum seeker population.
Fresenius Kabi Limited has informed the MHRA of an error on the infusion bag packaged into the specific batches of Sodium Chloride Intravenous Infusion 0.9% Freeflex.
Guidance for people with symptoms of a respiratory infection including COVID-19, or a positive test result for COVID-19.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.